Targeting Oxytocin Receptor: A Novel Strategy Against Hepatocellular Carcinoma Using Atosiban
Highlight
– Aberrant activation of the Hippo/YAP signaling pathway is critical in hepatocellular carcinoma (HCC) development.
– The oxytocin receptor (OXTR), a G protein-coupled receptor, activates Hippo/YAP signaling via Gq/11 and fosters a positive feedback loop facilitating liver cancer progression.
– Atosiban, an OXTR antagonist and established tocolytic agent, effectively disrupts this positive feedback, suppressing tumor growth in multiple preclinical HCC models.
– This discovery opens an avenue to repurpose Atosiban and highlights OXTR as a promising therapeutic target in HCC, addressing an unmet clinical need for effective treatment strategies.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.